Owners, management and financials
CVR: 34623562
Secondary names: Oncology Venture Product Development ApS
Previous names: ONCOLOGY VENTURE ApS, Oncology Venture Product Development ApS
DKK -38,996,000
Gross profit
Net result: DKK -17,793,000
Allarity Acquisition Subsidiary, Inc. (100%)
CVR · view owners
Steen Meier Knudsen, Jeffrey Stuart Ervin
CVR · view management
Active
Founded 1 August 2012
CVR · view overview
4 employees
CVR · 2026
Director role ended: Alexander Epshinsky
CVR · 04/07/2025
View the full event history
Allarity Therapeutics Europe ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Oncology Venture Product Development ApS and ONCOLOGY VENTURE ApS. The management consists of Steen Meier Knudsen and Jeffrey Stuart Ervin. The company is owned by Allarity Acquisition Subsidiary, Inc.. The company has 4 employees (2026). In 2025, the company reported a gross profit of DKK -38,996,000 and a net result of DKK -17,793,000 compared with DKK -393,818,000 the year before. Equity in the 2025 report amounted to DKK -216,588,000.
Selskabets formål er at investere eller på anden måde være engageret i virksomheder, der beskæftiger sig med diagnostik og lægemiddeludvikling, herunder individualiseret medicin til kræftbehandling. Selskabet kan yde konsulent- og managementbistand til selskaber. The object of the company is to invest or otherwise be engaged in businesses that are involved in diagnostics and development of medicinal products, including individualized medicinal products for the treatment of cancer. The company may offer consultancy and management assistance to other companies.
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | - | -17.8M | 25.8M | -216.6M | 4 | |
| 202401/01/2024 – 31/12/2024 | - | -393.8M | 11.2M | -198.8M | 4 | |
| 202301/01/2023 – 31/12/2023 | - | -48.7M | 362.2M | 195M | 5 | |
| 202201/01/2022 – 31/12/2022 | - | -142.4M | 365.9M | 243.8M | 5 | |
| 202101/01/2021 – 31/12/2021 | - | -76.3M | 498.8M | 386.3M | 0 | |
| 202001/01/2020 – 31/12/2020 | - | -18.6M | 38.2M | -147.1M | 3 | |
| 201901/01/2019 – 31/12/2019 | - | -34M | 40.3M | -128.5M | 6 | |
| 201801/01/2018 – 31/12/2018 | - | -30.8M | 32.9M | -94.5M | 3 | |
| 201701/01/2017 – 31/12/2017 | - | -43.6M | 45M | -63.7M | 3 | |
| 201601/01/2016 – 31/12/2016 | - | -23.1M | 32.8M | -20.1M | - | |
| 201501/01/2015 – 31/12/2015 | - | -7.3M | 18.7M | 1.3M | - | |
| 201401/01/2014 – 31/12/2014 | 61K | -422K | 574K | 485K | - |
Compared to 129 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreThe CVR number of Allarity Therapeutics Europe ApS is 34623562.
Allarity Therapeutics Europe ApS is owned by Allarity Acquisition Subsidiary, Inc..
The management of Allarity Therapeutics Europe ApS consists of Steen Meier Knudsen and Jeffrey Stuart Ervin.
In 2025, Allarity Therapeutics Europe ApS reported a gross profit of DKK -38,996,000.
Allarity Therapeutics Europe ApS had 4 employees in 2026 according to the Danish CVR register.
Allarity Therapeutics Europe ApS was founded on 1 August 2012.
Claim this page to add your logo and social links. Free to get started.
Contact info changed: new phone: 53639637 (September 11, 2026).
As of September 1, 2026, Cedra Godkendt Revisionsaktieselskab has been appointed auditor of Allarity Therapeutics Europe ApS.
As of September 1, 2026, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of Allarity Therapeutics Europe ApS.
Allarity Therapeutics Europe ApS has published its annual report for 2025. Gross profit came to DKK -38,996,000, and the net result was DKK -17,793,000.
As of July 4, 2025, Jeffrey Stuart Ervin is registered as director of Allarity Therapeutics Europe ApS.
As of July 4, 2025, Alexander Epshinsky has stepped down as director of Allarity Therapeutics Europe ApS.
Allarity Therapeutics Europe ApS has published its annual report for 2024. Gross profit came to DKK -44,548,000, and the net result was DKK -393,818,000.
As of September 12, 2024, Alexander Epshinsky is registered as director of Allarity Therapeutics Europe ApS.
As of September 12, 2024, Joan Yvonne Brown has stepped down as director of Allarity Therapeutics Europe ApS.
Allarity Therapeutics Europe ApS has published its annual report for 2023. Gross profit came to DKK -49,354,000, and the net result was DKK -48,735,000.
As of April 23, 2024, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Allarity Therapeutics Europe ApS.
As of December 12, 2023, Steen Meier Knudsen is registered as adm. dir. of Allarity Therapeutics Europe ApS.
As of December 12, 2023, James G. Cullem has stepped down as adm. dir. of Allarity Therapeutics Europe ApS.
As of December 11, 2023, Steen Meier Knudsen has stepped down as director of Allarity Therapeutics Europe ApS.
Allarity Therapeutics Europe ApS has published its annual report for 2022. Gross profit came to DKK -42,967,000, and the net result was DKK -142,438,000.
As of August 1, 2022, Steen Meier Knudsen is registered as director of Allarity Therapeutics Europe ApS.
Allarity Therapeutics Europe ApS has published its annual report for 2021. Gross profit came to DKK -79,617,000, and the net result was DKK -76,279,000.
As of July 25, 2022, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of Allarity Therapeutics Europe ApS.
As of June 29, 2022, James G. Cullem is registered as adm. dir. of Allarity Therapeutics Europe ApS.
As of June 29, 2022, Joan Yvonne Brown is registered as director of Allarity Therapeutics Europe ApS.
As of June 29, 2022, Stefano Roberto Carchedi has stepped down as adm. dir. of Allarity Therapeutics Europe ApS.
As of June 28, 2022, James G. Cullem has stepped down as director of Allarity Therapeutics Europe ApS.
As of June 27, 2022, Jens Erik Knudsen has stepped down as director of Allarity Therapeutics Europe ApS.
As of February 1, 2022, James G. Cullem is registered as director of Allarity Therapeutics Europe ApS.
As of December 23, 2021, Jens Erik Knudsen is registered as director of Allarity Therapeutics Europe ApS.
As of December 23, 2021, Stefano Roberto Carchedi is registered as adm. dir. of Allarity Therapeutics Europe ApS.
As of December 23, 2021, Thomas Henrik Jensen has stepped down as adm. dir. of Allarity Therapeutics Europe ApS.
On December 23, 2021, the company changed its name from Oncology Venture Product Development ApS to Allarity Therapeutics Europe ApS.
As of December 21, 2021, is registered as an owner of Allarity Therapeutics Europe ApS with an ownership share of 100%.
Allarity Therapeutics Europe ApS has published its annual report for 2020. Gross profit came to DKK -13,158,000, and the net result was DKK -18,557,000.
As of October 20, 2020, Thomas Henrik Jensen is registered as adm. dir. of Allarity Therapeutics Europe ApS.
As of October 20, 2020, Henrik Kristian Moltke has stepped down as adm. dir. of Allarity Therapeutics Europe ApS.
Allarity Therapeutics Europe ApS has published its annual report for 2019. Gross profit came to DKK -27,706,000, and the net result was DKK -33,965,000.
As of September 30, 2019, Henrik Kristian Moltke is registered as adm. dir. of Allarity Therapeutics Europe ApS.
As of September 30, 2019, Peter Buhl has stepped down as director of Allarity Therapeutics Europe ApS.
Allarity Therapeutics Europe ApS has published its annual report for 2018. Gross profit came to DKK -40,913,000, and the net result was DKK -30,821,000.
As of December 11, 2018, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Allarity Therapeutics Europe ApS.
As of December 11, 2018, EY Godkendt Revisionspartnerselskab has stepped down as auditor of Allarity Therapeutics Europe ApS.
As of December 11, 2018, Steen Meier Knudsen has left the board of directors of Allarity Therapeutics Europe ApS.
As of December 11, 2018, Ulla Hald Buhl has left the board of directors of Allarity Therapeutics Europe ApS.
As of December 11, 2018, Peter Birk Rasmussen has left the board of directors of Allarity Therapeutics Europe ApS.
As of December 11, 2018, Duncan Charles McNaught Moore has left the board of directors of Allarity Therapeutics Europe ApS.
As of December 11, 2018, Carani Balarman Sanjeevi has left the board of directors of Allarity Therapeutics Europe ApS.
On August 17, 2018, the company changed its name from ONCOLOGY VENTURE ApS to Oncology Venture Product Development ApS.
Allarity Therapeutics Europe ApS has published its annual report for 2017. Gross profit came to DKK -32,986,246, and the net result was DKK -43,604,140.
Allarity Therapeutics Europe ApS has published its annual report for 2016. Gross profit came to DKK -26,150,595, and the net result was DKK -23,071,168.
Allarity Therapeutics Europe ApS has published its annual report for 2015. Gross profit came to DKK -6,346,465, and the net result was DKK -7,321,761.
As of May 26, 2016, EY Godkendt Revisionspartnerselskab has been appointed auditor of Allarity Therapeutics Europe ApS.
As of May 26, 2016, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of Allarity Therapeutics Europe ApS.
Allarity Therapeutics Europe ApS has published its annual report for 2014. Revenue came to DKK 61,367, and the net result was DKK -422,442.
As of May 5, 2015, Steen Meier Knudsen has joined the board of directors of Allarity Therapeutics Europe ApS.
As of May 5, 2015, Jørgen Søberg Petersen has left the board of directors of Allarity Therapeutics Europe ApS.
As of February 6, 2015, Ulla Hald Buhl has joined the board of directors of Allarity Therapeutics Europe ApS.
As of February 6, 2015, Jørgen Søberg Petersen has joined the board of directors of Allarity Therapeutics Europe ApS.
As of February 6, 2015, Peter Birk Rasmussen has joined the board of directors of Allarity Therapeutics Europe ApS.
As of February 6, 2015, Duncan Charles McNaught Moore has joined the board of directors of Allarity Therapeutics Europe ApS.
As of February 6, 2015, Carani Balarman Sanjeevi has joined the board of directors of Allarity Therapeutics Europe ApS.
Allarity Therapeutics Europe ApS has published its interim report for the period August 1, 2012 to December 31, 2013.
As of August 1, 2012, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Allarity Therapeutics Europe ApS.
As of August 1, 2012, Peter Buhl is registered as director of Allarity Therapeutics Europe ApS.
Allarity Therapeutics Europe ApS was founded on August 1, 2012.
Companies in the same industry and area
CVR 38445928
CVR 29526346
CVR 37728403
CVR 40279865
CVR 63717916
